Clinical Trials Logo

Clinical Trial Summary

It has been reported that better local control is achieved and sphincters are preserved at a higher rate with curative resections performed after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancers. In addition, it has been reported that local recurrence is reduced and survival is prolonged in patients with complete pathological response to neoadjuvant therapy. Therefore, the importance of predicting patients with pathological complete response has increased. It has been reported that data obtained from PET-CT scans and clinical information such as tumor size, T stage, and N stage may be useful in predicting the response to neoadjuvant therapy in patients with locally advanced rectal cancer. Consideration of blood biomarkers in predicting neoadjuvant response can be a very attractive option. Because samples are easily collected, relatively inexpensive to measure, and contain information about different aspects of tumor biology. There are a limited number of blood biomarkers such as CEA and IL-6 that have been studied in the literature. Experimental studies show that vitamin D suppresses inflammation and protects against cancer by triggering differentiation. In 1980, Cedric and Frank Garland stated for the first time that vitamin D may affect the survival of the patient after the diagnosis of colorectal cancer. In later studies, a positive relationship was reported between the serum level of 25-hydroxyvitamin D - 25 (OH) D and survival rates for colorectal cancer, breast and prostate cancer. In addition, 25 (OH) D serum concentration has been shown to be inversely related to colorectal cancer progression. In the light of all these information, the role of serum vitamin D levels before neoadjuvant treatment in predicting pathological response in patients with rectal cancer is investigated in this study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04857203
Study type Observational [Patient Registry]
Source Istanbul Training and Research Hospital
Contact Cihad Tatar, MD
Phone +905336599889
Email [email protected]
Status Recruiting
Start date September 1, 2020
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Recruiting NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Suspended NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Active, not recruiting NCT02438839 - Curative Chemoradiation of Low Rectal Cancer
Completed NCT02399813 - Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Phase 2
Completed NCT02626728 - A Prospective Feasibility Study for TAMIS N/A
Recruiting NCT02592304 - Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT N/A
Completed NCT02236884 - The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer Phase 1/Phase 2
Completed NCT02243267 - GI SPORE Colon Biosample Protocol N/A
Recruiting NCT02280070 - RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). Phase 2
Completed NCT01938027 - The Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision N/A
Completed NCT02112747 - Adherence to Colon Cancer Screening (ACCS) N/A